The present disclosure features a skin mimetic, including a base layer including a hydrogel; and a top layer including a synthetic stratum corneum. The skin mimetic mimics a skin portion of a human subject, such as a facial skin portion. In an embodiment, the skin mimetic can serve as a mimic for a cheek skin portion, for example, for use in the testing of cosmetic products, therapeutic agents, moisturizers, shaving products, other skin care products, and the like.

Provided herein are methods for directing differentiation of human pluripotent stem cells into a three-dimensional multilayered skin composition comprising an epidermal layer, a dermal layer, and a plurality of cells capable of forming a functional hair follicle. Also provided herein are three-dimensional, multilayered engineered skin compositions and methods of using the same for drug screening, for screening compounds for effects on hair growth, and for other applications.

Allografts for soft tissue repair, including breast reconstruction and other plastic surgery procedures, are disclosed. One allograft is made from decellularized dermal tissue and constitutes a collagen matrix having substantially uniform density and porosity. Another allograft is a hybrid bilayer tissue form that is made from decellularized dermal and adipose tissues. Methods for making both allografts are also disclosed.

Disclosed herein are tissue treatment products that have been bound to at least one chelating agent. Also disclosed are tissue treatment products that have been functionalized with at least one metal and/or at least one metal-binding protein. The tissue treatment products can have antimicrobial properties and/or factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the tissue treatment products. The tissue treatment products can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration and can promote or enhance native cell migration, proliferation, and/or revascularization.

The present invention concerns a tissue-engineered medical device, as well as a method for the production said medical device, comprising the following steps: providing a polymer scaffold comprising a mesh comprising polyglycolic acid, and a coating comprising poly-4-hydroxybutyrate; application of a cell suspension containing preferably human cells to the polymer scaffold; placement of the seeded polymer scaffold in a bioreactor and mechanical stimulation by exposure to a pulsatile flux of incremental intensity, thereby forming an extracellular matrix; mounting of the graft on a conduit stabilizer and incubation in cell culture medium; decellularisation of the graft in a washing solution; nuclease treatment of the graft; and rinsing of graft. The invention further comprises and various steps of quality control of the tissue-engineered medical device.

Methods and systems for stiffening of tissue are presented to allow improved processing. Solutions including an acid or a base can be contacted with tissue to stiffen one or more components of the tissue. The resulting stiffened tissue can be used in the creation of wound treatment devices.

A transfer dressing that can secure and/or prevent undesired movement of epidermal skin grafts transfer substrates is described. The transfer dressing can include a transfer substrate and one or more adhesive appendages that are configured to secure the transfer substrate to a recipient site (e.g., periwound area) in order to hold the transfer substrate in place and/or facilitate handling of the transfer substrate. The transfer substrate can be comprised of a fenestrated surface configured to facilitate harvesting and transfer of epidermal skin grafts.

The invention of biological dura mater patch and a preparation method thereof. Raw material of patch does not come from commercial meat animals, but from breeding animals, such as SIS patch of the sow, has natural good mechanical properties; the method uses plant-derived reagents in the decellularization process, no damage to ECM natural structural base, and retain more active ingredients, has a better ability to induce tissue repair and growth; neither uses a cross-linking agent to enhance mechanical properties, nor synthetic detergents used to remove cells; chemical residues and their toxicity are avoided, while more effective ingredients in ECM, especially GAGs be retained. The patch has soft texture and good toughness, easy to sew tightly, and prevent cerebrospinal fluid leakage; and degradation rate is basically synchronized with the growth of the new dura mater, which is more conducive to repair and regeneration of dura mater.

The present disclosure provides methods and systems for printing a three-dimensional (3D) material. In some examples, a method for printing a 3D biological material comprises providing a media chamber comprising a medium comprising (i) a plurality of cells and (ii) one or more polymer precursors. Next, at least one energy beam may be directed to the medium in the media chamber along at least one energy beam path that is patterned into a 3D projection wherein the x, y, and z dimensions may be simultaneously accessed in accordance with computer instructions for printing the 3D biological material in computer memory, to form at least a portion of the 3D biological material comprising (i) at least a subset of the plurality of cells, and (ii) a polymer formed from the one or more polymer precursors.

The present disclosure provides tissue products produced from a combination of three-dimensional biologic scaffolds and acellular tissue matrices. The tissue products may include features for suture or fixation reinforcement. The tissue products may harness various properties of different acellular tissue matrices and different three-dimensional biologic scaffolds to provide improved composite structures with desired mechanical and/or biologic properties.